CSIR՚s Anti-Cancer Drug IIIM-290 Enters Clinical Trial

⪻ On New Articles ⪼

CSIR՚s Anti-Cancer Drug IIIM-290 Enters Clinical Trial

  • Indian institute of Integrative Medicine (IIIM) , Jammu has received Investigational New Drug (IND) approval from CDSCO (Central Drugs Standard Control Organization) for a potent anti-cancer NCE (New Chemical Entity) effective against pancreatic cancer.
  • It has successfully completed preclinical development and IND submission.
  • IIIM, Jammu is a CSIR constituent lab.
CSIR՚s Anti-Cancer Drug IIIM-290 Enters Clinical Trial

Overview

  • This will pave way for CSIR-IIIM for conducting the clinical trial of this important drug candidate IIIM-290 in pancreatic cancer patients.
  • The proposed clinical trial will assess the safety, tolerability and exposure of the compound in humans along with the early efficacy indicators in pancreatic cancer patients.
  • This drug was discovered and developed at the natural products driven drug discovery program of CSIR-IIIM.
  • The researchers conducted close to a decade of high end research as a prelude to granting of regulatory approval for clinical trials against pancreatic cancer.
  • Pancreatic cancer currently ranks 12th among most common cancers globally.
  • It has the notorious distinction of being the 4th leading cause of cancer-related deaths.
  • The pancreatic cancer incidence in India is
    • 0.5 - 2.4 per 100,000 in men
    • 0.2 - 1.8 per 100,000 in women.
  • Globally more than a quarter of a million deaths are caused by it.
  • Due to its late diagnosis, it is considered one of the untreatable cancer types.
  • There is a huge scarcity of drugs for the treatment of this cancer.
  • The indigenous drug discovery program based on natural products opens potential therapeutic options for pancreatic cancer.

Developed by: